EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1

Helene Geddert a,*, Axel zur Hausen b,***, Helmut E. Gabbert * and Mario Sarbia c,****

a Institute of Pathology, University Hospital of Düsseldorf, Düsseldorf, Germany
b Institute of Pathology, University Hospital of Freiburg, Freiburg, Germany
c Institute of Pathology, Technical University of Munich, Munich, Germany

Abstract. Background: Epstein–Barr virus (EBV)-associated gastric carcinomas (GC) constitute a distinct clinicopathological entity of gastric cancer. In order to determine underlying distinct aberrant promoter methylation we tested cardiac and non-cardiac GC with regard to the presence of EBV.

Methods: One hundred GC were tested by RNA-in situ hybridization for the presence of EBV by EBV-encoded small RNA (EBER). Aberrant promoter methylation was investigated by methylation-specific real-time PCR for p16, p14, APC and hMLH1. P16 protein expression was assessed by immunohistochemistry.

Results: In our selected study cohort, EBER-transcripts were detected in 19.6% (18/92) of GC. EBV-positive GC revealed significantly more often gene hypermethylation of p16, p14 and APC (p < 0.0001, p < 0.0001 and p = 0.02, respectively) than EBV-negative GC. The majority of GC with p16 hypermethylation showed a p16 protein loss (22/28). In contrast, no correlation between the presence of EBV and hMLH1 hypermethylation was found (p = 0.7). EBV-positive GC showed a trend towards non-cardiac location (p = 0.06) and lower stages (I/II) according to the WHO (p = 0.05).

Conclusions: Hypermethylation of tumor suppressor genes is significantly more frequent in EBV-associated GC compared to EBV-negative GC. Our data add new insights to the role of EBV in gastric carcinogenesis and underline that EBV-associated GC comprise a distinct molecular-pathologic as well as a distinct clinicopathological entity of GC.

Keywords: Gastric, cancer, cardia, EBV, methylation

1. Introduction

Diverse human malignancies have been linked to the Epstein–Barr virus (EBV), e.g., nasopharyngeal carcinoma, Burkitt’s lymphoma and gastric carcinoma (GC) [30,37]. Approximately 10% of GC worldwide are associated with the presence of EBV which ren-

*Corresponding author: Helene Geddert, Institute of Pathology, St. Vincentius Hospital, Südendstraße 37, 76137 Karlsruhe, Germany. Tel.: +49 721 8108 3006; Fax: +49 721 8108 3700; E-mail: Helene.Geddert@vincentius-ka.de.
**Present address: Institute of Pathology, St. Vincentius Hospital, Karlsruhe, Germany.
***Present address: Department of Pathology, University Hospital Maastricht, Maastricht, The Netherlands.
****Present address: Institute of Pathology, Munich-Nymphenburg, Germany.
patients are very sparse [34]. The tumor suppressor genes p16, p14 and APC have been reported to be hypermethylated in GC at varying frequencies (range 10–84%) [3,5,6,13,14,22,23]. The hypermethylation of the DNA mismatch repair gene hMLH1 often occurs in a setting of microsatellite instability and was found only in EBV-negative GC so far [16]. In the present study we related the methylation status of p16, p14, APC and hMLH1 to the presence of EBV in GC. Since cardiac and non-cardiac GC (located in body or antrum) are characterized by distinct molecular alterations [10], 50 carcinomas from each tumor localization were analyzed. Further, EBV-status was correlated to the available clinicopathological features [12,21,31,32], in order to determine if aberrant promoter hypermethylation can be added to the list of distinct molecular changes of EBV-associated GC possibly contributing to EBVaGC as distinct clinicopathological entity.

2. Methods

2.1. Case selection and tissue microarrays

From a large ongoing study [10,26], we selected 50 patients with a carcinoma of the gastric cardia and 50 carcinomas, located in the distal stomach, namely in the body and antrum. Cardiac GC were defined as type II and type III carcinomas from the esophago-gastric junction, according to the classification of Siewert and Stein [29]. Type I carcinomas (Barrett carcinomas) were excluded. All tumors were adeno-carcinomas, partly with signet ring histology. Details on application of WHO-classification and Lauren’s classification have been described previously [24]. Characteristics of patients and carcinomas are summarized in Table 1.

2.2. EBER-RNA in situ hybridization

The EBV-status of the GC had been tested previously by EBER-RNA in situ hybridization (RISH) on tissue microarrays (TMA) [26]. The TMAs contained three 0.6 mm thick punches per tumor (Beecher Instruments, Silver Spring, MD, USA) and only for signet ring cell carcinomas six instead of three punches were used. One complete and tumor bearing core per case was regarded as sufficient for the evaluation of the EBV-status according to previous results that EBV-associated GC do not reveal heterogeneity with respect to EBER-transcript expression [38]. One of 50 cardiac carcinomas and 7 of 50 gastric carcinomas were excluded from further analyses due to technical reasons, e.g., loss of tissue cores during RISH. Thus, in 49 cardiac and 43 distal gastric carcinomas a specific result could be achieved.

2.3. Methylation specific PCR

Details of methylation specific real-time PCR (MSP) for APC, p16INK4A, p14ARF, hMLH1 and control gene MYOD1 have been published previously [3,7]. In brief, genomic DNA from formalin-fixed, paraffin-embedded carcinoma tissue and corresponding tumor-free gastric smooth muscle tissue which served as constitutive negative control, were prepared under light microscopic control as published before [2,10,25]. For MSP, 1 µg of genomic DNA was modified using a CpG modification kit (CpG Genome™ DNA modification kit, Intergen, Purchase, NY, USA) according to the manufacturer’s protocol. Real-time MSP was performed in a Lightcycler (Roche Diagnostics,
Table 2

Sets of primers and probes for the investigated gene loci and conditions of methylation-specific PCR (MSP)

| Locus | Primer and probe set (5′FAM and 3′TAMRA) | MSP-Conditions |
|-------|------------------------------------------|----------------|
| APC   | F: GAA CCA AAA CGC TCC CCA T R: TTA TAT GTC GGT TGT GTG TTA TAT Probe: CCC GTC GAA AAC CCG CCG ATT A | (1) 10 min 95°C, (2) 10 s 95°C, (3) 5 s 58°C, (4) 8 s 72°C, (5) → 60 cycles (2)–(4) (6) 30 s 40°C |
| p16INK4A | F: TGG AGT TTT CGG TTG ATT GGT T R: AAC AAC GCC CGC ACC TCC T Probe: ACC CGA CCC CGA ACC GCG | (1) 10 min 95°C, (2) 10 s 95°C, (3) 5 s 58°C, (4) 8 s 72°C, (5) → 60 cycles (2)–(4) (6) 30 s 40°C |
| p14ARF | F: ACG GCC GTT TTC GTG AGT T R: CCG AAC CTC CAA AAT CTC GA Probe: CGA CTC TAA ACC CTA CGC ACG CGA AA | (1) 10 min 95°C, (2) 10 s 95°C, (3) 5 s 60°C, (4) 8 s 72°C, (5) → 60 cycles (2)–(4) (6) 30 s 40°C |
| hMLH1 | F: CGT TAT ATA TCG TTT GTA TCC GTG TTT R: CTA TCG CCG CCT CAT CGT Probe: CGC GAC GTC AAA CGC CAC TAC G | (1) 10 min 95°C, (2) 10 s 95°C, (3) 5 s 61°C, (4) 8 s 72°C, (5) → 60 cycles (2)–(4) (6) 30 s 40°C |
| MYOD1 | F: GGA TTT ATA TTT ATG TGG TTG GTG G R: CCA ACT CCA AAT CCC CTC TCT AT Probe: TCC CTT CCT ATT CCT AAT TCC AAC CTA AAT ACC T | (1) 10 min 95°C, (2) 10 s 95°C, (3) 5 s 61°C, (4) 8 s 72°C, (5) → 60 cycles (2)–(4) (6) 30 s 40°C |

Mannheim, Germany) using the Taqman technology. We selected previously published primers and probes, and in addition established new primers and probes [8]. Primer sequences and MSP conditions are summarized in Table 2.

2.4. Immunohistochemistry

The p16 protein expression was investigated in all cases with p16 hypermethylation by immunohistochemistry as published before [11,25]. Briefly, slides from one representative tumor block per case were stained using a monoclonal p16-antibody (Clone 16P07; Neomarkers, Westinghouse, CA, USA) at a dilution of 1:50 according to a standard avidin-biotin-peroxidase protocol. In 4 of 32 cases non-specific positivity was observed and these cases therefore were excluded.

2.5. Statistics

Statistical analyses were performed by the program SAS, version 9.1 [27]. Using the $X^2$-test $p$-values < 0.05 were considered as statistically significant. For analysis of age, patients were dichotomized before in two groups, younger or older than 60 years, respectively. For analysis of tumor diameter, patients were dichotomized before in two groups, less or more than 50 mm, respectively.

3. Results

Out of 92 GC, EBV-positive carcinomas ($n = 18$, Fig. 1) were significantly more often methylated
than EBV-negative adenocarcinomas \( (n = 74) \): While 83.3\% (15/18) of EBVaGC were methylated in p16, only 23.0\% (17/74) of EBV-negative GC were methylated in p16 \( (p < 0.0001) \). The majority of EBVaGC (88.9\%; 16/18) was also methylated in p14, but only a minority of EBV-negative GC (5.4\%; 4/74) \( (p\text{-value} < 0.0001) \). Since 83.3\% (15/18) of EBVaGC were methylated in APC, 54.1\% of EBV-negative cases were positive for APC methylation \( (p = 0.02) \).

In contrast, no association between EBV-status and methylation of hMLH1 was detected \( (p = 0.7) \). Accordingly, hMLH1 was methylated in 6/18 (33.3\%) of EBVaGC and 21/74 (28.4\%) of EBV-negative GC.

The majority of carcinomas with p16 hypermethylation revealed a concomitant p16 protein loss (22/28, 78.6\%).

12 of 43 (27.9\%) non-cardiac GC were EBV-associated, while only 6 of 49 (12.3\%) cardiac GC were EBV-positive, showing a trend towards more EBV-infections in the distal stomach \( (p = 0.06) \).

Further, we proved 15 of 58 (25.9\%) carcinomas of a lower stage (I and II) to be EBV-positive, but only 3 of 34 carcinomas in stages III and IV (8.8\%), although this correlation marginally failed to reach statistical significance \( (p = 0.05) \).

All results are summarized in Table 3.

### 4. Discussion

There are several indications, that aberrant methylation might be a central molecular mechanism of EBV-infection in gastric carcinoma cells. When viral DNA enters a cell, it is often deactivated by methylation. This leads to repression of viral protein expression and escape of immune surveillance of cells with oncogenic potential. But the EBV-induced methylation also affects the adjacent host DNA [22] and can even occur genome-wide [6]. This may result in inactivated tumor suppressor genes.

Gene silencing by aberrant methylation (hypermethylation) of the tumor suppressor genes p16, p14, and APC and of hMLH1 are prevalent findings in GC [9, 10, 25]. In the present study, we proved that methylation of these tumor suppressor genes is important mechanism in EBVaGC. The actually epigenetic silencing is demonstrated by p16 protein loss in most methylated cases.

These results have been confirmed by other authors, so far mostly in Asian patients [6, 16, 20]. Similar to our results, Chong and co-workers [6] proved 88.2\% of methylation in p14 and p16 each, which was significantly associated with EBV positivity [6]. These findings of high-density methylation strengthen the hypothesis that EBV-infection causes a de novo and maintenance of methylation [23].

Similar to our results, Kang and co-workers found multiple genes, e.g., APC and p16 being hypermethylated in a frequency >90% in EBVaGC, defining a so-called methylator phenotype [16]. EBV-positive GC show a concordant methylation of multiple genes very much like to microsatellite instable (MSI) GC, although in our and other studies EBVaGC usually show no MSI and vice versa [16]. In our study EBV-infection was not associated with hMLH1 hypermethylation, which is a marker for MSI. These results,
which are corroborated by other investigators, indicate that EBV induces a malignant pathway, independent of MSI [22].

The different molecular pathways of EBV-positive GC are reflected by different genetic aberration. EBV-associated GC are characterized by distinct chromosomal aberrations and in addition distinct patterns of allelic losses, e.g., at the TP53 locus including p53 immunoreactivity, are associated with the EBV-status [33,39]. Furthermore, underlying the distinct molecular pathology, EBV-associated GC reveal a unique type of EBV-latency, which is mainly characterized by the expression of the viral oncogene BARF1 and the absence of LMP1 [4,18,38].

These molecular differences are also reflected by the finding that EBV-associated GC comprise a distinct clinicopathological entity: EBV-associated GC are linked to male predominance, lower age, intestinal histological type, proximal location and a favorable prognosis [31,32,38].

The purpose of our study was not to investigate the clinico-pathological parameters associated with the prevalence of EBV, but the impact of differences in promoter methylation with regard to EBV. However, the identification of the tight association to aberrant methylation of p16, p14 and APC in EBVaGC in this study, which was not observed to that extent in EBV-negative GC, strongly underline together with the missing association to hMLH1 hypermethylation that EBVaGC comprise a distinct clinicopathological entity.

Acknowledgements

We thank R. Willers, Computer Center, Heinrich-Heine-University Düsseldorf for statistical analyses. The excellent technical assistance of Mrs. H. Huss and Mrs. C. Pawlik is greatly appreciated.
References

[1] M.D. Begnami, A.L. Montagnini, A.L. Vettore, S. Nonogaki, M. Bratt, A.Y. Simoes-Sato, A.Q. Seixas and F.A. Soares, Differential expression of apoptosis related proteins and nitric oxide synthases in Epstein–Barr associated gastric carcinomas, World J. Gastroenterol. 12 (2006), 4959–4965.

[2] R.L. Brücher, H. Geddert, C. LANGNER, H. Höfler, U. Fink, J.R. Siewert and M. Sarbia, Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary adenocarcinomas of the small bowel, Int. J. Cancer 119 (2006), 1298–1302.

[3] M.S. Chang, H. Uozaki, J.M. Chong, T. Ushiku, K. Sakuma, S. Ishikawa, R. Hino, R.R. Barua, Y. Iwasaki, K. Arai, H. Fuji, H. Nagai and M. Fukayama, CpG island methylation status in gastric carcinoma with and without infection of Epstein–Barr virus, Clin. Cancer Res. 12 (2006), 2995–3002.

[4] F. Chapel, B. Fabiani, F. Davi, M. Tepper, G. Kampault and C. Guettier, Epstein–Barr virus and gastric carcinoma in Western patients: comparison of pathological parameters and p53 expression in EBV-positive and negative tumours, Histopathology 36 (2000), 252–261.

[5] J.M. Chong, K. Sakuma, M. Sudo, T. Osawa, E. Ohara, H. Uozaki, J. Shibahara, K. Kuroiwa, S. Tominaga, Y. Hippo, H. Aburatani, N. Funata and M. Fukayama, Interleukin-1beta expression in human gastric carcinoma with Epstein–Barr virus infection, J. Virology 76 (2002), 6828–6831.

[6] J.M. Chong, K. Sakuma, M. Sudo, T. Ushiku, H. Uozaki, J. Shibahara, H. Nagai, N. Funata, H. Taniguchi, H. Aburatani and M. Fukayama, Global and non-random CpG-island methylation in gastric carcinoma associated with Epstein–Barr virus, Cancer Sci. 94 (2003), 76–80.

[7] C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, D. Shibata, P.W. Laird, MethyLight: a high-throughput assay to measure DNA methylation, Nucleic Acids Res. 28 (2000), E32.

[8] C.A. Eads, R.V. Lord, K. Wickramasinghe, T.I. Long, S.K. Kurumboor, L. Bernstein, J.H. Peters, S.R. DeMeester, T.R. DeMeester, K.A. Skinner and P.W. Laird, Methylation patterns in the progression of esophageal adenocarcinoma, Cancer Res. 61 (2001), 3410–3418.

[9] M. Esteller, A. Almendro, M. Sanchez-Cespedes, C. Capellam, M.A. Peinado, S. Gonzalez, G. Tarafa, D. Sidransky, S.J. Meltzer, S.B. Baylin and J.G. Herman, Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer, Cancer Res. 60 (2000), 4366–4371.

[10] H. Geddert, S. Kiel, E. Iskender, A.R. Flør, T. Krieg, S. Vossen, H.E. Gabbert and M. Sarbia, Correlation of hMLH1 and HPP1 hypermethylation in gastric, but not in esophageal and cardiac adenocarcinoma, Int. J. Cancer 110 (2004), 208–211.

[11] H. Geddert, M. Zerihou, M. Wolter, J.W. Heise, H.E. Gabbert and M. Sarbia, Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions, Am. J. Clin. Pathol. 118 (2002), 60–66.

[12] M.L. Gulley, D.R. Pultizer, P.A. Eagan and B.G. Schneider, Epstein–Barr virus infection is an early event in gastric carcinogenesis and is independent of bel-2 expression and p53 accumulation, Hum. Pathol. 27 (1996), 20–27.

[13] S. Iida, Y. Akiyama, T. Nakajima, W. Ichikawa, Z. Nii, K. Sugihara and Y. Yuasa, Alterations and hypermethylation of the p14(ARF) gene in gastric cancer, Int. J. Cancer 87 (2000), 654–658.

[14] H.H. Ishii, G.C. Gobe, J. Yoneyama, M. Mukaida and Y. Ebihara, Role of p53, apoptosis, and cell proliferation in early stage Epstein–Barr virus positive and negative gastric carcinomas, J. Clin. Pathol. 57 (2004), 1306–1311.

[15] C. Koriyama, S. Kitajima, M. Nomoto, K. Sueyoshi, T. Itoh, Y. Eizuru, S. Yonezawa and S. Akiba, Loss of p16/CDKN2A protein in Epstein–Barr virus-associated gastric carcinoma, Oncology 67 (2004), 81–87.

[16] G.H. Kang, S. Lee, W.H. Kim, H.W. Lee, J.C. Kim, M.G. Ryu and J.Y. Ro, Epstein–Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma, Am. J. Pathol. 160 (2002), 787–794.

[17] H.S. Lee, M.S. Chang, H.K. Yang, B.L. Lee and W.H. Kim, Epstein–Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein–Barr virus-negative gastric carcinoma, Clin. Cancer Res. 10 (2004), 1698–1705.

[18] B. Luo, Y. Wang, X.F. Wang, H. Liang, L.P. Yan, B.H. Huang and P. Zhao, Expression of Epstein–Barr virus genes in EBV-associated gastric carcinomas, World J. Gastroenterol. 11 (2005), 629–633.

[19] B. Luo, Y. Wang, X.F. Wang, Y. Gao, B.H. Huang and P. Zhao, Correlation of Epstein–Barr virus and its encoded proteins with Helicobacter pylori and expression of c-met and c-myc in gastric carcinoma, World J. Gastroenterol. 12 (2006), 1842–1848.

[20] T. Osawa, J.M. Chong, M. Sudo, K. Sakuma, H. Uozaki, J. Shibahara, H. Nagai, N. Funata and M. Fukayama, Reduced expression and promoter methylation of p16 gene in Epstein–Barr virus-associated gastric carcinoma, Jpn. J. Cancer Res. 93 (2002), 1195–1200.

[21] K. Qu, Y. Tomita, M. Hashimoto, M. Ohsawa, K. Kawano, D.M. Wu and K. Aozasa, Epstein–Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: association with clinico-pathologic factors and HLA-subtype, Int. J. Cancer 71 (1997), 155–158.

[22] R. Remus, C. Kammer, H. Heller, B. Schmitt, G. Schell and W. Doerfler, Insertion of foreign DNA into an established mammalian genome can alter the methylation of cellular DNA sequences, J. Virology 73 (1999), 1010–1022.

[23] K. Sakuma, J.M. Chong, M. Sudo, T. Ushiku, Y. Inoue, J. Shibahara, H. Uozaki, H. Nagai and M. Fukayama, High-density methylation of p14ARF and p16INK4A in Epstein–Barr virus-associated gastric carcinoma, Int. J. Cancer 112 (2004), 273–278.

[24] M. Sarbia, The histological appearance of oesophageal adenocarcinoma – an analysis based on 215 resection specimens, Virchows Arch. 448 (2006), 532–538.

[25] M. Sarbia, H. Geddert, B. Klump, S. Kiel, E. Iskender and H.E. Gabbert, Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract, Int. J. Cancer 111 (2004), 224–228.

[26] M. Sarbia, A. zur Hausen, M. Feith, H. Geddert, B.H. von Rathden, C. Langer, C. von Weyhern, J.R. Siewert, H. Höfler and H.J. Stein, Esophageal (Barrett’s) adenocarcinoma is not associated with Epstein–Barr virus infection: an analysis of 162 cases, Int. J. Cancer 117 (2005), 698–700.
[27] SAS Institute Inc., SAS/STAT User’s Guide, Version 9.1, Cary, NC: SAS Institute Inc., 2004.
[28] D. Shibata and L.M. Weiss, Epstein–Barr virus-associated gastric adenocarcinoma, *Am. J. Pathol.* **140** (1992), 769–774.
[29] J.R. Siewert and H. Stein, Classification of adenocarcinomas of the esophago-gastric junction, *Br. J. Cancer* **85** (1998), 1457–1459.
[30] M.P. Thompson and R. Kurzrock, Epstein–Barr virus and cancer, *Clin. Cancer Res.* **10** (2004), 803–821.
[31] M. Tokunaga, C.E. Land, Y. Uemura, T. Tokudome, S. Tanaka and E. Sato, Epstein–Barr virus in gastric carcinoma, *Am. J. Pathol.* **143** (1993), 1250–1254.
[32] J. van Beek, A. zur Hausen, E.K. Kranenburg, C.J. van de Velde, J.M. Middeldorp, A.J. van den Brule, C.J. Meijer and E. Bloemena, EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement, *J. Clin. Oncol.* **22** (2004), 664–670.
[33] B.P. van Rees, E. Caspers, A. zur Hausen, A. van den Brule, P. Drillenburg, M.A. Weterman and G.J. Offerhaus, Different pattern of allelic loss in Epstein–Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway, *Am. J. Pathol.* **161** (2002), 1207–1213.
[34] Q.N. Vo, J. Geradts, M.L. Gulley, D.A. Boudreau, J.C. Bravo and B.G. Schneider, Epstein–Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation, *J. Clin. Pathol.* **55** (2002), 669–675.
[35] Q. Wang, S.W. Tsao, T. Ooka, J.M. Nicholls, H.W. Cheung, S. Fu, Y.C. Wong and X. Wang, Anti-apoptotic role of BARF1 in gastric cancer cells, *Cancer Lett.* **238** (2006), 90–103.
[36] T. Wiech, E. Nikolopoulos, S. Lassmann, T. Heidt, A. Schöpflin, M. Sarbia, M. Werner, Y. Shimizu, E. Sakka, T. Ooka and A. zur Hausen, Cyclin D1 expression is induced by viral BARF1 and is overexpressed in EBV-associated gastric cancer, *Virology* **352** (2008), 621–627.
[37] L.S. Young and A.B. Rickinson, Epstein–Barr virus: 40 years on, *Nat. Rev. Cancer* **4** (2004), 757–768.
[38] A. zur Hausen, A.A. Brink, M.E. Craanen, J.M. Middeldorp, C.J. Meijer and A.J. van den Brule, Unique transcription pattern of Epstein–Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene, *Cancer Res.* **60** (2000), 2745–2748.
[39] A. zur Hausen, N.C. van Grieken, G.A. Meijer, M.A. Hermsen, E. Bloemena, S.G. Meuwissen, J.P. Baak, C.J. Meijer, E.J. Kuipers and A.J. van den Brule, Distinct chromosomal aberrations in Epstein–Barr virus-carrying gastric carcinomas tested by comparative genomic hybridization, *Gastroenterology* **121** (2001), 612–618.